In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer

Gefitinib, a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is recommended for treatment of non-small cell lung cancer (NSCLC) patients who harbor activating EGFR mutations. However, the tumors of most patients initially sensitive to gefitinib will develop resistance within several mont...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cancer
Autores principales: Sha, Huanhuan, Dong, Shuchen, Yu, Chen, Zou, Renrui, Zhu, Yue, Lu, Ya, Zhang, Junying, Cao, Haixia, Chen, Dan, Wu, Jianzhong, Feng, Jifeng
Formato: Artigo
Lenguaje:Inglês
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646187/
https://ncbi.nlm.nih.gov/pubmed/33193885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.46461
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares